Clinical Circulating Tumor DNA Testing for Precision Oncology

키워드

참고문헌 (87)

1. Mandel P, "Nuclear acids in human blood plasma", CR Seances Soc Biol Fil, 142, pp.241~243 (1948)
2. Sorenson GD, "Soluble normal and mutated DNA sequences fromsingle-copy genes in human blood", Cancer Epidemiol Biomarkers Prev, 3, pp.67~71 (1994)
3. Nawroz H, "Microsatellite alterations in serum DNA of head and neck cancerpatients", Nat Med, 2, pp.1035~1037 (1996)
4. Stroun M, "About the possible origin and mechanism of circulating DNA apoptosis and active DNA release", Clin Chim Acta, 313, pp.139~142 (2001)
5. Diaz LA Jr, "Liquid biopsies : genotyping circulating tumor DNA", J Clin Oncol, 32, pp.579~586 (2014)
6. Pantel K, "Circulating tumour cells in cancer patients : challenges and perspectives", Trends Mol Med, 16, pp.398~406 (2010)
7. Diehl F, "Detection and quantification of mutations in the plasma of patients with colorectal tumors", Proc Natl Acad Sci U S A, 102, pp.16368~16373 (2005)
8. Jahr S, "DNA fragments in the blood plasma of cancer pati-ents : quantitations and evidence for their origin from apoptotic and necrotic cells", Cancer Res, 61, pp.1659~1665 (2001)
9. Sacher AG, "Prospective validation of rapid plasmagenotyping for the detection of EGFR and KRAS mutations in advanced lung cancer", JAMA Oncol, 2, pp.1014~1022 (2016)
10. Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2008)
11. Umetani N, "Prediction of breast tumor progression by integrity of free circulating DNA in serum", J Clin Oncol, 24, pp.4270~4276 (2006)
12. Li L, "Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection", Sci Rep, 6, pp.23992~ (2016)
13. Lehmann-Werman R, "Identification of tissue-specific cell death using methylation patterns of circulatingDNA", Proc Natl Acad Sci U S A, 113, pp.E1826~34 (2016)
14. Schwarzenbach H, "Cell-free nucleic acidsas biomarkers in cancer patients", Nat Rev Cancer, 11, pp.426~437 (2011)
15. Xie M, "Age-related mutations associated with clonal hematopoietic expansion and malignancies", Nat Med, 20, pp.1472~1478 (2014)
16. Genovese G, "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence", N Engl J Med, 371, pp.2477~2487 (2014)
17. Jaiswal S, "Age-related clonal hematopoiesis associatedwith adverse outcomes", N Engl J Med, 371, pp.2488~2498 (2014)
18. Wan JC, "Liquid biopsies come of age : towardsimplementation of circulating tumour DNA", Nat Rev Cancer, 17, pp.223~238 (2017)
19. Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies", Sci Transl Med, 6, pp.224ra24~ (2014)
20. Cisneros-Villanueva M, "Cell-free DNA analysis in current cancer clinical trials : a review", Br JCancer, 126, pp.391~400 (2022)
21. Pantel K, "Real-time liquid biopsy in cancer patients : fact or fiction?", Cancer Res, 73, pp.6384~6388 (2013)
22. Bronkhorst AJ, "Towards systematic nomenclature for cell-free DNA", Hum Genet, 140, pp.565~578 (2021)
23. "Create professional science figures in minutes" (2022)[URL]
24. Keller L, "Clinical relevanceof blood-based ctDNA analysis : mutation detection andbeyond", Br J Cancer, 124, pp.345~358 (2021)
25. Gray ES, "Genomic analysis of circulating tumor DNA using amelanoma-specific UltraSEEK Oncogene Panel", J Mol Diagn, 21, pp.418~426 (2019)
26. Kohn L, "Liquid biopsies in lung cancer-time to implement research technologies inroutine care?", Ann Transl Med, 5, pp.278~ (2017)
27. Diehl F, "BEAMing : single-molecule PCR on microparticles in water-in-oil emulsions", Nat Methods, 3, pp.551~559 (2006)
28. Sorber L, "Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision ofpersonalized therapy for lung cancer patients", Lung Cancer, 107, pp.100~107 (2017)
29. Santis G, "Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR", PLoS One, 6, pp.e25191~ (2011)
30. Castellanos-Rizaldos E, "Temperature-tolerant COLD-PCR reducestemperature stringency and enables robust mutation enrichment", Clin Chem, 58, pp.1130~1138 (2012)
31. Narayan A, "Ultrasensitive measurement of hotspotmutations in tumor DNA in blood using error-suppressedmultiplexed deep sequencing", Cancer Res, 72, pp.3492~3498 (2012)
32. Newman AM, "Integrated digital error suppression forimproved detection of circulating tumor DNA", Nat Biotechnol, 34, pp.547~555 (2016)
33. Dressman D, "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations", Proc Natl Acad Sci U S A, 100, pp.8817~8822 (2003)
34. Dang DK, "Circulating tumor DNA : current challenges for clinical utility", J Clin Invest, 132, pp.e154941~ (2022)
35. Chen M, "Next-generation sequencing in liquid bio-psy : cancer screening and early detection", Hum Genomics, 13, pp.34~ (2019)
36. Mosko MJ, "Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry", J Mol Diagn, 18, pp.23~31 (2016)
37. Arisi MF, "Circulating tumor DNA inprecision oncology and its applications in colorectal cancer", Int J Mol Sci, 23, pp.4441~ (2022)
38. Baer C, "Ultra-deep sequencing leads to earlier andmore sensitive detection of the tyrosine kinase inhibitor resi-stance mutation T315I in chronic myeloid leukemia", Haematologica, 101, pp.830~838 (2016)
39. Soda N, "Recent advances in liquid biopsy technologies for cancer biomarker detection", Sens Diagn, 1, pp.343~375 (2022)
40. Underhill HR, "Fragment length of circulating tumor DNA", PLoS Genet, 12, pp.e1006162~ (2016)
41. Chen A, "Comparison of paired cerebrospinal fluid and serum cell-free mitochondrial and nuclear DNA with copy number and fragmentlength", J Clin Lab Anal, 34, pp.e23238~ (2020)
42. Cristiano S, "Genome-wide cell-free DNA fragmentation in patientswith cancer", Nature, 570, pp.385~389 (2019)
43. Cai Z, "Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing", J Mol Diagn, 22, pp.860~870 (2020)
44. Arzimanoglou II, "Microsatellite instability in human solid tumors", Cancer, 82, pp.1808~1820 (1998)
45. Cortes-Ciriano I, "A mole-cular portrait of microsatellite instability across multiple cancers", Nat Commun, 8, pp.15180~ (2017)
46. Boyiadzis MM, "Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease", J Immunother Cancer, 6, pp.35~ (2018)
47. Niu B, "MSIsensor : microsatellite instability detection using paired tumor-normal sequence data", Bioinformatics, 30, pp.1015~1016 (2014)
48. Salipante SJ, "Microsatellite instability detection by next generation sequencing", Clin Chem, 60, pp.1192~1199 (2014)
49. Kautto EA, "Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS", Oncotarget, 8, pp.7452~7463 (2017)
50. Suva ML, "Epigenetic reprogramming in cancer", Science, 339, pp.1567~1570 (2013)
51. Luo H, "Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer", Sci Transl Med, 12, pp.eaax7533~ (2020)
52. "GRAIL and the quest for earlier multi-cancer detection" (2018)[URL]
53. Koch A, "Analysis of DNA methylation in cancer : location revisited", Nat Rev Clin Oncol, 15, pp.459~466 (2018)
54. Daniunaite K, "Epigenomic technologies for deciphering circulating tumor DNA", Curr Opin Biotechnol, 55, pp.23~29 (2019)
55. Colella S, "Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites", Biotechniques, 35, pp.146~150 (2003)
56. Tost J, "Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing", Biotechniques, 35, pp.152~156 (2003)
57. Wong IH, "Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients", Cancer Res, 59, pp.71~73 (1999)
58. Wojdacz TK, "Methylation-sensitive high-resolution melting", Nat Protoc, 3, pp.1903~1908 (2008)
59. Xia Y, "Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma : a single-arm, open label, phase II clinical trial", J Immunother Cancer, 10, pp.e004656~ (2022)
60. Openshaw MR, "Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma", Br J Cancer, 123, pp.1271~1279 (2020)
61. Martinez-Saez O, "Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4", 6inhibition and endocrine therapy, 2021, pp.7, 8~
62. Engel T, "Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn’s disease", Inflamm Bowel Dis, 21, pp.2320~2326 (2015)
63. Wang X, "The DEAD-box RNA helicase 51 controls non-small cell lung cancer proliferation by regulating cell cycle progression via multiple pathways", Sci Rep, 6, pp.26108~ (2016)
64. Merker JD, "Circulating tumor DNA analysis in patients with cancer : American Society of Clinical Oncology and College of American Pathologists Joint Review", Arch Pathol Lab Med, 142, pp.1242~1253 (2018)
65. El Messaoudi S, "Circulating cell free DNA : preanalytical considerations", Clin Chim Acta, 424, pp.222~230 (2013)
66. Norton SE, "A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR", Clin Biochem, 46, pp.1561~1565 (2013)
67. Toro PV, "Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA", Clin Biochem, 48, pp.993~998 (2015)
68. Barra GB, "EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples", Clin Biochem, 48, pp.976~981 (2015)
69. Li D, "FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology", Precis Cancer Med, 4, pp.32~ (2021)
70. Gong B, "Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions", Genome Biol, 22, pp.109~ (2021)
71. Deveson IW, "Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology", Nat Biotechnol, 39, pp.1115~1128 (2021)
72. Zhang Y, "Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples", Genome Biol, 23, pp.141~ (2022)
73. Willey JC, "Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA", Cell Rep Methods, 1, pp.100106~ (2021)
74. "Drug Approvals and database" (2020)[URL]
75. Duffy MJ, "Use of circulating tumour DNA(ctDNA)for measurement of therapy predictive biomarkers in patients with cancer", J Pers Med, 12, pp.99~ (2022)
76. Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 2. 2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
77. Corcoran RB, "Liquid biopsy versus tumor biopsy for clinical-trial recruitment", Nat Med, 26, pp.1815~1816 (2020)
78. Ghosh RK, "Liquid biopsy : a new avenue inpathology", Cytopathology, 30, pp.138~143 (2019)
79. Marrugo-Ramirez J, "Blood-based cancerbiomarkers in liquid biopsy : a promising non-invasive alternative to tissue biopsy", Int J Mol Sci, 19, pp.2877~ (2018)
80. Chae YK, "Detection of minimal residual diseaseusing ctDNA in lung cancer : current evidence and futuredirections", J Thorac Oncol, 14, pp.16~24 (2019)
81. Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease", Cancer Discov, 11, pp.2968~2986 (2021)
82. Pellini B, "Circulating tumor DNA minimalresidual disease detection of non-small-cell lung cancer treated with curative intent", J Clin Oncol, 40, pp.567~575 (2022)
83. Parikh AR, "Minimal residual disease detectionusing a plasma-only circulating tumor DNA assay in patients with colorectal cancer", Clin Cancer Res, 27, pp.5586~5594 (2021)
84. Menikoff J, "The common rule, upda-ted", N Engl J Med, 376, pp.613~615 (2017)
85. Dresser R, "Research ethics. Aligning regulations and ethics in human research", Science, 337, pp.527~528 (2012)
86. Detsky AS, "Sources of bias for authors of clinical practiceguidelines", CMAJ, 175, pp.1033~ (2006)
87. Sturgeon CM, "Laboratory medicine practiceguidelines. Use of tumor markers in clinical practice: qualityrequirements", National Academy of Clinical Biochemistry, ~ (2009)

관련 논문AI추천